T. T. Nguyen

发表

Potential implications of matrix metalloproteinase-9 in assessment and treatment of coronary artery disease

D. Fryburg, S. Terra, R. Wolk, 2009, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

The pharmacokinetics of PF-734200, a DPP-IV inhibitor, in subjects with renal insufficiency.

R. Boyd, T. Marbury, S. Terra, 2011, British journal of clinical pharmacology.

Novel ATP 7 B mutations in Vietnamese patients with Wilson disease

D. Tran, T. Ho, K. V. Tran, 2016 .

CLINICAL CASE SEMINAR Familial Splenomegaly: Macrophage Hypercatabolism of Lipoproteins Associated with Apolipoprotein E Mutation (Apolipoprotein E (D149 Leu))

R. Mahley, I. Hay, T. Crotty, 2000 .

Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.

C. Contant, S. Terra, A. Lewin, 2008, The American journal of cardiology.

A Case-Control Study of Meat Mutagens and Colorectal Cancers in Viet Nam

L. Dang, T. T. Nguyen, Hoc Hieu Tran, 2020, Asian Pacific journal of cancer prevention : APJCP.

Non‐traditional biomarkers of atherosclerosis in stable and unstable coronary artery disease, do they differ?

D. Fryburg, S. Terra, R. Wolk, 2007, Acute cardiac care.

Fractures After Thyroidectomy in Men: A Population‐Based Cohort Study

W. O'Fallon, L. Melton, S. Bryant, 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Cholesterol-lowering effect of stanol ester in a US population of mildly hypercholesterolemic men and women: a randomized controlled trial.

I. Croghan, L. Dale, K. von Bergmann, 1999, Mayo Clinic proceedings.

Predictors of macrovascular disease in patients with type 2 diabetes mellitus.

D. Hodge, H. Abu-Lebdeh, T. T. Nguyen, 2001, Mayo Clinic proceedings.

Effect of thyroid hormone replacement on lipoprotein(a), lipids, and apolipoproteins in subjects with hypothyroidism.

C. Morillas, A. Hernández-Mijares, M. Martínez-Triguero, 1998, Mayo Clinic proceedings.

The effect of the treatment of hypothyroidism and hyperthyroidism on plasma lipids and apolipoproteins AI, AII and E

D. Hodge, I. Hay, B. Kottke, 1997, Clinical endocrinology.

The American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Dyslipidemia and Prevention of Atherogenesis 2002 Amended Version

H. Rodbard, O. Ganda, P. Jellinger, 2002 .

The American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Dyslipidemia and Prevention of Atherogenesis

H. Rodbard, O. Ganda, P. Jellinger, 2000 .

Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women.

K. Bailey, D. Hodge, T. Kottke, 1997, Circulation.

HDL subparticles and coronary artery disease in NIDDM.

K. Bailey, D. Hodge, B. Kottke, 1994, Atherosclerosis.

The role of lipoprotein A-I and lipoprotein A-I/A-II in predicting coronary artery disease.

K. Bailey, D. Hodge, D. Holmes, 1995, Arteriosclerosis, thrombosis, and vascular biology.

Response to Comments from Ntanios et al. Regarding “The Cholesterol-Lowering Action of Plant Stanol Esters”

T. T. Nguyen, 2000 .

The pharmacokinetics of PF-734200, a DPP-IV inhibitor, in subjects with renal insufficiency.

R. Boyd, T. Marbury, S. Terra, 2011, British journal of clinical pharmacology.

A Dose-Ranging Study of the DPP-IV Inhibitor PF-734200 Added to Metformin in Subjects With Type 2 Diabetes*.

S. Schwartz, J. Teeter, S. Terra, 2011, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor PF‐734200 added to metformin in Type 2 diabetes

J. Rosenstock, J. Teeter, P. Norwood, 2011, Diabetic medicine : a journal of the British Diabetic Association.